Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study

Zhong, Hua; Yang, Huan; Mao, Zhuxin; Chai, Xiaoyun; Li, Shunping

doi:10.1186/s12955-021-01902-w

“…However, a notable proportion also had negative attitudes. This supports previous research showing that patients with psoriasis often experience negative emotions, social exclusion, and stigmatization ( 27 – 29 ). However, other studies have reported positive attitudes among patients who actively seek treatment and engage in self-care practices, leading to better quality of life ( 30 , 31 ).…”

Section: Discussionsupporting

confidence: 92%

Knowledge, attitude, and practice of psoriasis patients toward their diseases: a web-based, cross-sectional study

Tian,

Zhang,

Zhao

et al. 2024

Front. Med.

0

View full text Add to dashboard Cite

ObjectiveTo investigate the knowledge, attitude, and practice (KAP) of psoriasis patients toward the disease.MethodsA web-based cross-sectional study was conducted among psoriasis patients who were diagnosed at the outpatient of Shaanxi Provincial People’s Hospital in March 2023. A self-designed questionnaire was administered for data collection and KAP assessment.ResultsA total of 526 valid questionnaires were included, including 257 males (48.86%) psoriasis patients. Their mean KAP scores were 8.09 ± 3.60 (possible range: 0–12), 31.94 ± 4.61 (possible range: 10–50), and 51.92 ± 8.83 (possible range: 15–75), respectively. Pearson’s correlation analysis showed a positive correlation between knowledge and attitude (r = 0.186, p < 0.001), a positive correlation between knowledge and practice (r = 0.313, p < 0.001), and a negative correlation between attitude and practice (r = −0.181, p < 0.001). Moreover, structural equation model showed that medication (β = 2.74, 95% CI: 2.17, 3.32, p < 0.001) has significantly positive effect on knowledge. Education (β = 0.56, 95% CI: 0.31, 0.81, p < 0.001) and duration of psoriasis (β = 1.01, 95% CI: 0.54, 1.49, p < 0.001) have significantly positive effect on attitude. Knowledge (β = 1.03, 95% CI: 0.80, 1.26, p < 0.001) and medication (β = 4.59, 95% CI: 2.78, 6.40, p < 0.001) has significantly positive effect on practice, while attitude (β = −0.41, 95% CI: −0.57, −0.26, p < 0.001) and duration of psoriasis (β = −2.53, 95% CI: −3.49, −1.57, p < 0.001) exhibit significantly negative effect on practice.ConclusionPsoriasis patients have good knowledge, positive attitude, and proactive practice toward the disease. Education, medication, duration of psoriasis might have effect on their KAP.

show abstract

“…The study examined many aspects of patients' lives that psoriasis affected including the symptoms, management of the symptoms, functioning, activities of daily living, psychological and social impact, as well as finances and employment. The findings of the study demonstrated that psoriasis had a negative impact on patients' lives and lowered the QoL (Zhong et al, 2021).…”

Section: Discussionmentioning

confidence: 86%

Successful treatment of secukinumab in severe plaque psoriasis

Damayanti

¹

,

Prakoeswa

²

,

Anggraeni

³

et al. 2022

ijhs

1

0

View full text Add to dashboard Cite

Psoriasis is a persistent, chronic condition that manifests on the skin, joints, and other visible places that compromises the quality of life. The vast understanding of the pathophysiology of psoriasis has led to a rise in the use of biological therapy in treating psoriasis in recent years. A 48-year-old woman with severe plaque psoriasis was previously treated with methotrexate and phototherapy for 3 months, however, the treatment showed no significant improvement. The patient was then treated with a biological agent, namely secukinumab, with a dose of 150 mg weekly for 5 weeks followed by one dose a month later. The symptoms were improved considerably after 10 weeks of observation, which indicated by the decrease in Psoriasis Area Severity Index (PASI) score and the Dermatology Life Quality Index (DLQI) score. There was no significant side effect during the observation. This case showed that secukinumab therapy at a dose of 150 mg can successfully treat severe plaque psoriasis patient.

show abstract

“…IL-23, IL-12, and IL-17 have increasingly become new target molecules as research has progressed [25]. Studies have demonstrated that the IL-23 and IL-12 receptor antagonists, risankizumab and ustekinumab, could improve patients' well-being with psoriasis and the main outcomes for the assessment of the clinical effects include PASI and Dermatology Life Quality Index (DLQI) [26][27][28]. LOTUS [29], a phase-III clinical trial with 322 Chinese participants, is aimed at evaluating the effect of ustekinumab on moderate to severe psoriatic patients, and the results suggested that at week-12, the PASI75 reaction in patients receiving ustekinumab 45 mg (82.5%) was significantly higher than those who received placebo (11.1%).…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment

Yu

¹

,

Ge

²

,

Jing

³

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Biological targeted therapy serves as a new alternative treatment for psoriasis due to its minimal side effects. This study is aimed at examining the drug effectiveness and safety of risankizumab and ustekinumab for psoriasis treatment, so as to provide a reference for clinical decision-making. Databases from Embase, Web of Science, PubMed, and Cochrane Library were gathered, starting from inception to March 1, 2022, for randomized controlled trials regarding risankizumab and ustekinumab for psoriasis treatment. All retrieved articles were carefully selected in strict accordance with a set of inclusion and exclusion criteria. Stata 15.0 and RevMan 5.4 were applied to perform meta-analysis and risk of bias assessment. A total of two trials with three NCTs were selected, with 384 participants in the risankizumab group and 140 participants in ustekinumab. Meta-analysis showed that in the long-term and short-term PASI100, risankizumab was more effective than ustekinumab ( RR = 2.27 , 95% CI (1.77, 2.90), p < 0.05 ; RR = 2.33 , 95% CI (1.75, 3.08), p < 0.05 ). In PASI90, RR = 1.77 , 95% CI (1.54, 2.03), and p < 0.05 and RR = 1.72 , 95% CI (1.48, 2.00), and p < 0.05 . In short-term PASI75, RR = 1.23 , 95% CI (1.13, 1.34), and p < 0.05 . In sPGA of 0, the results at week-16 and week-52 showed that risankizumab was significantly more effective than ustekinumab ( RR = 2.24 , 95% CI (1.67, 3.01), p < 0.05 ; RR = 2.30 , 95% CI (1.80, 2.95), p < 0.05 ). Risankizumab was significantly more effective than ustekinumab in improving the quality of life and PSS scores ( RR = 1.48 , 95% CI (1.26, 1.75), p < 0.05 ; RR = 2.01 , 95% CI (1.41, 2.85), p < 0.05 ). Nevertheless, risankizumab and ustekinumab did not show significant difference in the incidence of adverse responses ( RR = 1.02 , 95% CI (0.75, 1.39), p > 0.05 ). Risankizumab was more effective than ustekinumab for the treatment of psoriasis. The adverse reactions of both risankizumab and ustekinumab were similar and could be tolerated. Risankizumab might be a better alternative option for their treatment.

show abstract

Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study

Cited by 15 publications

References 49 publications

Knowledge, attitude, and practice of psoriasis patients toward their diseases: a web-based, cross-sectional study

Knowledge, attitude, and practice of psoriasis patients toward their diseases: a web-based, cross-sectional study

Successful treatment of secukinumab in severe plaque psoriasis

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment

Contact Info

Product

Resources

About